Nephroprotective effect of Dichrostachys cinerea Bark Extract against Streptozotocin Induced Diabetic Nephropathy Via Alteration of Oxidative Stress and Inflammation

Introduction: The primary trigger of End-Stage Renal Disease (ESRD) in several affluent nations, including the US, is diabetic nephropathy. Objectives: Diabetic nephropathy is a microvascular consequence that can occur in patients with Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D). Because of its anti-inflammatory and antioxidant effects, Dichrostachys cinerea (L.) Wight and Arn. (DC) treats many inflammatory diseases, especially rheumatoid arthritis. Materials and Methods: The experimental rats were given an intraperitoneal dose of 60 mg/kg of STZ to cause diabetes. Following diabetic induction, fasting blood glucose samples were taken on the 0thand 30th day. Following the study, we evaluated the activity of pro-inflammatory indicators, renal biochemical markers, and levels of oxidative and antioxidant stress following DCBE treatment. Results: Glibenclamide is an anti-diabetic medication that was utilized in the study to compare treatment with DCBE. When DCBE was administered to STZ-induced diabetic rats, the levels of ROS, plasma AGEs, BUN, Serum Creatinine, uric acid, NAG, and U-mAIb were found to decrease. TNF-α, IL-1β, and IL-6 activities were all markedly downregulated. Following DCBE treatment, SOD, GSH, and GPx levels increased. Conclusion: According to the current investigation, DCBE treatment alleviated STZ-induced diabetes in a manner comparable to that of glibenclamide treatment. It might therefore be utilized as a possible treatment for diabetic nephropathy in the future.